Protox Therapeutics uses genetic engineering to transform naturally occurring proteins into novel targeted therapeutics for the treatment of prostate diseases and various cancers. Protox is advancing a pipeline of clinical-stage product candidates derived from its PORxin™ and INxin™ technology platforms. Protox’s lead drugs currently in clinical development include PRX302 for the treatment of benign prostatic hyperplasia (BPH, commonly known as enlarged prostate) and localized prostate cancer, as well as PRX321 for primary brain cancer (glioblastoma multiforme and astrocytoma).

What's New

June 2 2010
Protox Announces Positive Six Month Phase 2B BPH Results

June 1, 2010
Protox to Present Phase 2B BPH Data at the Annual Meeting of the American Urological Association

May 13, 2010
Protox Reports First Quarter 2010 Financial Results

April 29, 2010
Protox Signs $75 Million License Agreement with Kissei for Commercialization of PRX302 in Japan for BPH and Prostate Disease

Events

January 11, 2010 - 8:45 am ET
Protox Therapeutics Conference Call - Webcast Link

Stock Quote

	LAST TRADE:	$0.39
	TRADE TIME:	3:53PM EST
	CHANGE:	$0.00 (0.00%)
	PREV CLOSE:	$0.39
	OPEN:	$0.39
	BID:	$0.385
	ASK:	$0.39